Delving into the Latest Updates on Eluxadoline with Synapse

Overview

Basic Info

Drug Type

Small molecule drug

Synonyms

Eluxadoline (USAN), Mu Delta, TRUBERZI

+ [2]

Target

δ opioid receptor x κ opioid receptor x μ opioid receptor

Action

antagonists, agonists

Mechanism

δ opioid receptor antagonists(δ-opioid receptor antagonists), κ opioid receptor agonists(Kappa opioid receptor agonists), μ opioid receptor agonists(Mu opioid receptor agonists)

Therapeutic Areas

Digestive System DisordersOther Diseases

Active Indication

Irritable bowel syndrome with diarrheaIrritable Bowel SyndromeDiarrhea

Inactive Indication

Diabetes MellitusDiabetes Mellitus, Type 1Fecal Incontinence+ [2]

Originator Organization

Actavis

Active Organization

AbbVie, Inc.Allergan Pharma Co.Allergan, Inc. (Canada)

Inactive Organization

Allergan Pharmaceuticals International Ltd.Allergan UC

License Organization

Janssen Pharmaceuticals, Inc.

Forest Laboratories LLC

Furiex Pharmaceuticals, Inc.

Drug Highest PhaseApproved

First Approval Date

United States (27 May 2015),

Irritable Bowel Syndrome

RegulationFast Track (United States)

Login to view timeline

Structure/Sequence

Molecular FormulaC32H35N5O5

InChIKeyQFNHIDANIVGXPE-FNZWTVRRSA-N

CAS Registry864821-90-9

Diabetes is a chronic disease that affects a large part of the United States population. The majority of patients with diabetes will experience gastrointestinal symptoms. One of the most troublesome gastrointestinal symptoms that diabetes can cause is diarrhea, otherwise known as "Diabetic Diarrhea." This occurs because diabetes does damage to nerves that control the gut and prevent it from functioning normally. Currently, there are only several medications used to treat the symptoms of Diabetic Diarrhea, but many of these medications have serious side effects or do not work well.
We are investigating the drug eluxadoline for the treatment of Diabetic Diarrhea. Eluxadoline is a gut-specific medication that is FDA approved to treat diarrhea related to irritable bowel syndrome (IBS-D). Our hypothesis is eluxadoline will safely and successfully reduce diarrhea symptoms (number of stools and less liquid stools) and improve the quality of life in patients with Diabetic Diarrhea when compared with placebo. Each patient with Diabetic Diarrhea who participates will take both eluxadoline and a placebo drug at separate times over a period of several months as part of a crossover study design. While on each medication, eluxadoline or placebo, the participants will keep a diary of symptoms and will be followed by the medical team through a combination of office visits and questionnaires. There will be five planned office visits and intermittent phone calls (questionnaires, surveys) over the 140-day study period. Participants will not be permitted to use any other anti-diarrhea medication during the study period and will continue on medication for management of their diabetes.

Start Date01 Jul 2022

Sponsor / Collaborator

Temple University Graduate School

[+1]

NCT04880876

/ Enrolling by invitationPhase 3

A Phase 3, Long-term Safety Study of Oral Eluxadoline Administered to Pediatric Participants With Irritable Bowel Syndrome With Diarrhea (IBS-D)

This study will assess the long-term safety of oral Eluxadoline administered to pediatric participants with IBS-D who have completed study intervention in the Phase 2 study 3030-202-002 or the Phase 3 study 3030-303-002.

Start Date13 Aug 2021

Sponsor / Collaborator

AbbVie, Inc.

NCT03489265

/ WithdrawnPhase 2IIT

Treatment of Diarrhea-Associated Fecal Incontinence With Eluxadoline

Accidental bowel leakage (fecal incontinence) increases in people who have diarrhea and sensations of urgency to have a bowel movement. Drugs such as loperamide (Imodium) that reduce diarrhea improve accidental bowel leakage, but loperamide has disadvantages: it is difficult to find a dose that does not cause constipation, and it does not reduce urge sensations. Eluxadoline is a new drug that is effective for reducing diarrhea, abdominal pain, and urgency in patients with irritable bowel syndrome, and it may be less likely than loperamide to cause severe constipation. Therefore, eluxadoline may help patients manage accidental bowel leakage caused by diarrhea. The chemical name for Viberzi® is eluxadoline.
The primary aims of this study are to find out if eluxadoline at a dose of 100 mg orally twice a day will reduce the average number of days the patient has accidental bowel leakage, and to see if the rate of accidental bowel leakage increases when the patient stops taking eluxadoline. Additional goals are to find out if eluxadoline decreases diarrhea and urge sensations.
This is a small (pilot) study to show whether eluxadoline is an effective way of treating accidental bowel leakage. If the study shows this, a larger study will be needed. There are three phases to this 12-week study: (1) A two-week run-in period to see if the patient meets the inclusion criteria. (2) Two months for treatment including one month on eluxadoline and one on placebo (sugar pills) twice a day. (3) A two-week follow-up to see what happens when you stop taking eluxadoline.
To participate in the study, patients should be aged 18 or older. Patients with inflammatory bowel disease, anal fissures, or congenital malformations will be excluded.
The primary outcome is the average number of days per week with any solid or liquid bowel accidents. Additional information includes: (1) Number of days per week the patient takes loperamide, (2) days per week with loose or watery stools, (3) days per week with moderate to strong urge sensations, and (4) questionnaires to measure the severity of accidental bowel leakage, quality of life, anxiety, and depression. There will be up to 38 patients in the study.

Start Date01 Apr 2019

Sponsor / Collaborator

The University of North Carolina at Chapel Hill

[+1]

100 Clinical Results associated with Eluxadoline

Login to view more data

100 Translational Medicine associated with Eluxadoline

Login to view more data

100 Patents (Medical) associated with Eluxadoline

Login to view more data

142

Literatures (Medical) associated with Eluxadoline

04 Mar 2025·Expert Review of Gastroenterology & Hepatology

An evidence-based update on the diagnosis and management of irritable bowel syndrome

Review

Author: Black, Christopher J. ; Ford, Alexander C.

INTRODUCTION:

Irritable bowel syndrome (IBS) is a disorder of gut-brain interaction affecting 5% of the population. The cardinal symptoms are abdominal pain and altered stool form or frequency.

AREAS COVERED:

Diagnosis and management of IBS. We searched the literature for diagnostic accuracy studies, randomized controlled trials, and meta-analyses. A positive diagnosis of IBS, alongside testing to exclude celiac disease, is recommended. Exhaustive investigation has a low yield. Patients should be offered traditional dietary advice. If response is incomplete, specialist dietetic guidance should be considered. Probiotics may be beneficial, but quality of evidence is poor. First-line treatment of constipation is with laxatives, with secretagogues used where these are ineffective. Anti-diarrheal drugs should be used first-line for diarrhea, with second-line drugs including 5-hydroxytryptamine-3 antagonists, eluxadoline, or rifaximin, where available. First-line treatment of abdominal pain should be with antispasmodics, with gut-brain neuromodulators prescribed second-line. Low-dose tricyclic antidepressants, such as amitriptyline, are preferred. Brain-gut behavioral therapies are effective and have evidence for efficacy in patients refractory to standard therapies.

EXPERT OPINION:

Despite substantial advances, there remains scope for improvement in terms of both the diagnosis and management of IBS. Reinforcement of positive diagnostic strategies for the condition and novel treatment paradigms are required.

01 Sep 2024·JOURNAL OF PHARMACEUTICAL AND BIOMEDICAL ANALYSIS

A multi-analyte assay of opioids in API and drug products using HPLC and HRMS

Article

Author: Ngo, Diem ; Geerlof-Vidavsky, Ilan ; Gryniewicz-Ruzicka, Connie ; Stark, Matthew ; Balch, Maurie

Surveillance testing is an essential component to ensuring safe, effective, and high-quality drug products are available in the commercially marketed US supply chain. Surveillance allows the agency to assess product quality and monitor for potential adulteration of drug products being used by consumers. Opioid drug products can be adulterated to enhance the effect of the intended active ingredient. Numerous accounts have been reported where fentanyl has been used as an adulterant in illicit street drugs such as heroin, cocaine, or methamphetamine. To efficiently surveil the legitimate opioid supply chain, an analytical method with the ability to simultaneously detect, identify and quantify opioid molecules is desired. In this study, a multi-opioid protocol (MOP) using liquid chromatography-high resolution mass spectrometry (HPLC-HRMS) technology was developed and validated for the detection and quantification of 27 opioid drugs. The MOP analytical procedure was applied to the analysis of drug substance and finished dosage forms. MOP was used to identify and quantify active pharmaceutical ingredients (API) listed on the label claim, and in the case of suspected economically motivated adulteration could identify and quantify undeclared opioid APIs. The analytical method analysis time was 16 minutes and the LOD and LOQ in full MS mode were (average) 0.3 and 0.8 ng/mL, respectively. The validation criteria parameters were satisfactory based on international guidelines (ICH). The MOP was successfully applied to the analysis of over 160 drug substances and finished products. For all samples tested in the study, their identities were confirmed, and assays met specifications. Overall, there was no evidence of illegal substitution or adulteration in any of the ingredients and products tested from the legitimate commercial marketed US supply chain.

01 Jun 2024·Advances in therapy

Treatment-Free Interval: A Novel Approach to Assessing Real-World Treatment Effectiveness and Economic Impact Among Patients with Irritable Bowel Syndrome with Diarrhea

Article

Author: Guérin, Annie ; Dashputre, Ankur A ; Lacy, Brian E ; Bumpass, Brock ; Heimanson, Zeev ; Gagnon-Sanschagrin, Patrick ; Bungay, Rebecca ; Joseph, George ; Borroto, Danellys ; Bellefleur, Remi

INTRODUCTION:

Objective assessment of treatment effectiveness using real-world claims data is challenging. This study assessed treatment-free intervals (TFI) as a proxy for treatment effectiveness, and all-cause healthcare costs among adult patients with irritable bowel syndrome with diarrhea (IBS-D) treated with rifaximin or eluxadoline in the USA.

METHODS:

Adult patients (18-64 years) with IBS-D and ≥ 1 rifaximin or eluxadoline prescription were identified in the IQVIA PharMetrics^® Plus database (10/01/2015-12/31/2021) and classified into two mutually exclusive cohorts (i.e., rifaximin and eluxadoline). Index date was the date of rifaximin or eluxadoline initiation. Entropy-balanced baseline characteristics, TFI (periods of ≥ 30 consecutive days without IBS-D treatment), and healthcare costs were reported. Healthcare costs were compared between cohorts using mean cost differences.

RESULTS:

There were 7094 and 2161 patients in the rifaximin and eluxadoline cohorts, respectively. After balancing, baseline characteristics (mean age 44.1 years; female 72.4%) were similar between cohorts. A higher proportion of patients treated with rifaximin achieved a TFI of ≥ 30 days (76.2% vs. 66.7%), ≥ 60 days (67.0% vs. 47.0%), ≥ 90 days (61.0% vs. 38.7%), ≥ 180 days (51.7% vs. 31.0%), and ≥ 240 days (47.7% vs. 27.9%) compared to eluxadoline. Among patients with a TFI ≥ 30 days, mean TFI durations were 8.3 and 6.0 months for the rifaximin and eluxadoline cohorts. Mean all-cause healthcare costs were lower for rifaximin vs. eluxadoline ($18,316 vs. $23,437; p = 0.008), primarily driven by pharmacy costs ($7348 vs. $10,250; p < 0.001). In a simulated health plan of one million commercially insured lives, initiating 50% of patients on rifaximin instead of eluxadoline resulted in total cost savings of $2.1 million per year or $0.18 per-member-per-month.

CONCLUSIONS:

This real-world study suggests that TFI is a meaningful surrogate measure of treatment effectiveness in IBS-D. Patients treated with rifaximin had longer treatment-free periods and lower healthcare costs than patients treated with eluxadoline.

11

News (Medical) associated with Eluxadoline

19 Mar 2025

·pharma.economictimes.indiatimes.com

Zydus Lifesciences shares rally 3% after FDA approval for prostate cancer drug

Zydus Lifesciences shares rallied 3 per cent in early trade to a high of Rs 930.60 on the BSE on Wednesday after the company secured final approval from the US Food and Drug Administration ( USFDA ) to manufacture a generic version of Apalutamide tablets, used to treat prostate cancer. The approval covers Apalutamide tablets of 60 mg strength, the company said in a regulatory filing. The drug will be manufactured at Zydus Lifesciences ' SEZ facility in Ahmedabad. Apalutamide, an androgen receptor inhibitor, is prescribed for patients with metastatic castration-sensitive prostate cancer. It had annual US sales of $1,099.8 million, according to IQVIA MAT January 2025 data. Last week, Zydus Lifesciences also received USFDA approval to manufacture Eluxadoline tablets (75 mg and 100 mg), used to treat irritable bowel syndrome with diarrhea in adults. These will also be produced at the SEZ facility in Ahmedabad. Zydus was among the first to file an Abbreviated New Drug Application (ANDA) with a Paragraph IV certification for Eluxadoline tablets. This approval grants the company 180 days of shared generic exclusivity for the drug. Zydus Life shares target price As per Trendlyne data, the average target price of the stock is Rs 1,064, which shows an upside of 18% from the current market prices. The consensus recommendation from 31 analysts for the stock is a 'Hold'. Technically, the stock's relative strength index (RSI) is at 48. According to Trendlyne, an RSI below 30 is considered oversold, while above 70 indicates overbought conditions. Additionally, the MACD is at -16.1, which is below its center line, this is a bearish indicator. The stock is trading below its 30-day, 50-day, 100-day, 150-day, and 200-day simple moving averages (SMAs) but remains above its 5-day, 10-day, and 20-day SMAs. Zydus Life shares performance On Tuesday, Zydus Life shares closed at Rs 903.1, up 1.1 per cent on the BSE, while the benchmark Sensex surged 1.53%. The stock has declined 7 per cent year-to-date and 16 per cent in the last six months. The company’s market capitalization stands at Rs 90,872 crore.

Drug ApprovalAccelerated Approval

16 Mar 2025

·pharma.economictimes.indiatimes.com

Zydus diarrhoea generic secures FDA final nod

Ahmedabad: Zydus Lifesciences , announced that the United States Food and Drug Administration (FDA) has given its final approval to market and manufacture eluxadoline tablets . Eluxadoline, is a mu-opioid receptor agonist, indicated in adults for the treatment of irritable bowel syndrome with diarrhoea (IBS-D). The generic medication , will be manufactured at company’s Ahmedabad facility and will produce them in the dosage strength of 75 and 100 mg. As per IQVIA figures in the last annual till January 2025, eluxadoline tablets had annual sales of $243.7 million in the United States. The Indian drug maker claims itself as the first ANDA applicants to submit a substantially complete ANDA with a paragraph IV certification and is eligible for 180 days of shared generic drug exclusivity for the medication. In a stock exchange filing the company said that, post this approval the group now has 419 approvals and has so far filed 483 ANDAs since the commencement of the filing process in FY 2003-04. By Online Bureau ,

Drug Approval

04 Jun 2024

·www.prnewswire.com

Analysis Group Researchers Suggest a Novel Approach to Measuring Real-World Treatment Effectiveness for Irritable Bowel Syndrome with Diarrhea

BOSTON, June 4, 2024 /PRNewswire/ -- Researchers from Analysis Group, a global leader in health economics and outcomes research (HEOR), have coauthored a study detailing how treatment-free intervals (TFIs) can be an effective surrogate in retrospective data analyses for understanding therapy effectiveness for conditions that present multifaceted symptoms across widely divergent patient populations, such as irritable bowel syndrome with diarrhea (IBS-D). The study, published in the journal Advances in Therapy, is the first to use TFIs to assess real-world IBS-D therapy response, using two of the most commonly prescribed treatments in the US: rifaximin and eluxadoline. While the Food and Drug Administration (FDA) recommends using a five-item opinion-based questionnaire to measure patient-reported outcomes (PROs) that capture clinically important signs and symptoms to define treatment effects in clinical trials, it is challenging to apply this method to evaluate real-world outcomes in retrospective studies. The difficulty lies in the complex presentation of IBS-D, a common, chronic, relapsing, and potentially severe disorder of gut–brain interaction characterized by troublesome symptoms such as abdominal pain, diarrhea, fecal urgency, and bloating. To overcome these challenges, study investigators analyzed US commercial claims data for 9,255 IBS-D patients receiving one of the two treatments over the course of one year. The researchers focused on patients' TFI patterns – the length of time a patient remains off treatment after a course of therapy. Patient characteristics included age, sex, health plan type, region, and provider specialty, as of the index date. During baseline, medically relevant comorbidities (both gastrointestinal- and mental health–related), procedures (e.g., anesthesia, surgery, radiation services), and treatments were reported. Investigators specifically examined the duration of the index treatment, the number of prescription fills, and all-cause health care costs among adult patients with IBS-D treated with rifaximin or eluxadoline. The researchers concluded that TFIs may be a meaningful proxy for measuring treatment effectiveness in IBS-D. Using this method, they also found that patients treated with rifaximin had longer TFIs and lower health care costs than patients treated with eluxadoline. "The challenges of studying IBS-D are similar in many ways to those faced with oncology, where important treatment goals include medication-free periods associated with symptom control, especially when there is a treatment-related toxicity or financial burden associated with treatment changes or combination therapy," said study investigator Annie Guérin, a Managing Principal with Analysis Group. "Our approach to using TFIs was based on the proven strategies used in oncology, where patients value treatment-free periods because they are associated with improved health-related quality of life." The study, "Treatment-Free Interval: A Novel Approach to Assessing Real-World Treatment Effectiveness and Economic Impact Among Patients with Irritable Bowel Syndrome with Diarrhea," was published in April in Advances in Therapy. In addition to Ms. Guérin, investigators included Vice President Patrick S. Gagnon, Associate Rebecca Bungay, and Senior Research Professional Remi Bellefleur of Analysis Group; Brian E. Lacy of Mayo Clinic; Zeev Heimanson of Salix Pharmaceuticals; Brock Bumpass, Danellys Borroto, and Ankur A. Dashputre of Bausch Health; and George Joseph of BioNTech US. Funding was provided by Bausch Health. To learn more about Analysis Group's HEOR capabilities, visit About Analysis Group's HEOR, Epidemiology & Market Access Practice Founded in 1981, Analysis Group is one of the largest international economics consulting firms, with more than 1,200 professionals across 14 offices. Analysis Group's health care experts apply analytical expertise to health economics and outcomes research (HEOR), clinical research, market access and commercial strategy, and health care policy engagements, as well as drug safety-related engagements in epidemiology. Analysis Group's internal experts, together with our network of affiliated experts from academia, industry, and government, provide our clients with exceptional breadth and depth of expertise and end-to-end consulting services globally. Contact: Analysis Group Eric Seymour, +1 978 273 6049 [email protected] SOURCE Analysis Group

Radiation TherapyClinical ResultClinical Study

100 Deals associated with Eluxadoline

Login to view more data

External Link

KEGG	Wiki	ATC	Drug Bank
D10403	Eluxadoline	A07DA06	DB09272

R&D Status

Approved

10 top approved records.

Login

to view more data

Indication	Country/Location	Organization	Date
Irritable bowel syndrome with diarrhea	European Union	Allergan Pharmaceuticals International Ltd.	19 Sep 2016
Irritable bowel syndrome with diarrhea	Iceland	Allergan Pharmaceuticals International Ltd.	19 Sep 2016
Irritable bowel syndrome with diarrhea	Liechtenstein	Allergan Pharmaceuticals International Ltd.	19 Sep 2016
Irritable bowel syndrome with diarrhea	Norway	Allergan Pharmaceuticals International Ltd.	19 Sep 2016
Irritable Bowel Syndrome	United States	AbbVie, Inc.	27 May 2015

Developing

10 top R&D records.

Login

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Diabetes Mellitus	Phase 3	United States	Allergan UC	01 Jul 2022
Diabetes Mellitus, Type 1	Phase 3	United States	Allergan UC	01 Jul 2022
Diarrhea	Phase 3	United States	Allergan UC	01 Jul 2022
Fecal Incontinence	Phase 2	-	Allergan UC	01 Apr 2019
Intestinal Fistula	Phase 2	-	Allergan UC	01 Apr 2019
Urinary Incontinence, Urge	Phase 2	-	Allergan UC	01 Apr 2019

Login to view more data

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


NCT03441581 (3030-401-002, CTgov)	Phase 4	Irritable bowel syndrome with diarrhea \| Bile acid malabsorption	24	Eluxadoline (Eluxadoline 100 mg With BAM)	gqbjhehnzs(embczgpniq) = gawwplymtn ucezczylfj (gbdiglebwv, 0.639) View more	-	19 May 2021
				Eluxadoline (Eluxadoline 100 mg Without BAM)	gqbjhehnzs(embczgpniq) = thmlzntwka ucezczylfj (gbdiglebwv, 0.777) View more
NCT01130272 (CTgov)	Phase 2	Diarrhea \| Irritable Bowel Syndrome	807	Eluxadoline (Eluxadoline 5 mg)	brjpnmpbio = grigmjxkqq ipcdoikzoa (agiexgvxml, akzlaefwsx - qgrbrxjuyv) View more	-	22 Oct 2019
				Eluxadoline (Eluxadoline 25 mg)	brjpnmpbio = zxiqghqclx ipcdoikzoa (agiexgvxml, orfuaivrhm - fvowznyuxn) View more
NCT02959983 (RELIEF, Pubmed \| Am J Gastroenterol) Manual	Phase 4	Diarrhea \| Irritable Bowel Syndrome	346	Eluxadoline	nugdfenzpl(eoqkpvgxpq) = mesnewtpnh vyegrjltwv (nrnzyyjxzq ) View more	Positive	01 Sep 2019
				Placebo	nugdfenzpl(eoqkpvgxpq) = tkrfwvlqow vyegrjltwv (nrnzyyjxzq ) View more
NCT02959983 (RELIEF, CTgov)	Phase 4	Irritable bowel syndrome with diarrhea \| Diarrhea	346	Eluxadoline (Eluxadoline)	ocfbnshqtr = kfboybrznx zheqrbeosq (dvyjetlilz, qbpmurvyoa - vhgrrtivbg) View more	-	15 Feb 2019
				Placebo (Placebo)	ocfbnshqtr = kdlxccwxrj zheqrbeosq (dvyjetlilz, xbpwrnsbhs - nnivocpqcr) View more
NCT01553591 (CTgov)	Phase 3	Irritable bowel syndrome with diarrhea	1,282	Eluxadoline (Eluxadoline 75 mg)	pvjonuipxv = lxnczikpye kqkklvaeol (uinaikjttb, wregagvglw - ttkyjcdakm) View more	-	04 Sep 2018
				Eluxadoline (Eluxadoline 100 mg)	pvjonuipxv = zgqsldbgrg kqkklvaeol (uinaikjttb, rqwhsfbhui - gclqxgrjhx) View more
NCT01553747 (CTgov)	Phase 3	Irritable bowel syndrome with diarrhea	1,146	Eluxadoline (Eluxadoline 75 mg)	agowtcdizb = fayrjxjakw swuugdihmi (ymocxbjyec, nrzpujtuxc - xdbpigzeol) View more	-	30 Jul 2018
				Eluxadoline (Eluxadoline 100 mg)	agowtcdizb = jhikxqhfph swuugdihmi (ymocxbjyec, eaxfxbvols - swspmlpzcn) View more
UEGW2017	Not Applicable	Irritable bowel syndrome with diarrhea	-	Eluxadoline 75 mg	fjaxvxgdcl(vzljmmsuyc) = qrpmstgcnf amboetssux (ymwbxpfbly )	-	01 Oct 2017
				Eluxadoline 100 mg	fjaxvxgdcl(vzljmmsuyc) = gbctsbgtle amboetssux (ymwbxpfbly )
UEGW2016	Not Applicable	Irritable Bowel Syndrome	-	Eluxadoline 75 mg	zxbxcnrqoe(lhdibfbjsi) = rhocnqgxst nmzpynqsro (xboerzvars ) View more	-	01 Oct 2016
				Eluxadoline 100 mg	zxbxcnrqoe(lhdibfbjsi) = omorktklce nmzpynqsro (xboerzvars ) View more
NCT01553591 \| NCT01553747 (IBS-3001 and IBS-3002, Pubmed \| N Engl J Med)	Phase 3	Irritable bowel syndrome with diarrhea	2,427	Eluxadoline 75 mg	dolvdmwoan(hrmpdqgnjp) = fwqlcssqxz egxvfvfwtc (vyxlusjmwj ) View more	-	21 Jan 2016
				Eluxadoline 100 mg	dolvdmwoan(hrmpdqgnjp) = gxpyxyguna egxvfvfwtc (vyxlusjmwj ) View more
NCT01130272 (Pubmed \| J Laparoendosc Adv Surg Tech A \| Gastroenterology) Manual	Phase 2	Diarrhea \| Irritable Bowel Syndrome	807	Eluxadoline	tweguvhgal(bjphirxsqr) = yckdoyltew feovmjnutb (wwtcssaitk ) View more	Positive	01 Aug 2013
				Placebo	tweguvhgal(bjphirxsqr) = nxxodqjflg feovmjnutb (wwtcssaitk ) View more